Fang Dong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Fang Dong has a total of 212 co-authors. Here are the top co-authors by number of shared publications:
- Tao Cheng
Institute of Hematology and Blood Diseases Hospital
13 shared publications - Hui Cheng
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
9 shared publications - Hideo Ema
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
7 shared publications Jinglei Zhai
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
5 shared publicationsLisha Wang
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
5 shared publicationsJinhong Wang
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
4 shared publications
Latest Publications
- 5 November 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (19) , 2315-2317
Less is more: expanding human HSCs via a novel mimetic niche
- 5 November 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (19) , 2315-2317
Less is more: expanding human HSCs via a novel mimetic niche
- Open Access
The self-renewing lymphoid-biased hematopoietic stem cells support long-term lymphopoiesis in mice
Lymphopoiesis is profoundly impaired during ageing largely due to ageing-susceptible changes of hematopoietic stem cells (HSCs). How to maximize the preservation of lymphopoiesis during ageing remains unknown and whether there exists a specific population with life-long lymphoid potential not intensively affected by ageing is of substantial scientific and translational significance. Here, we identified a self-renewable, lymphoid-biased hematopoietic stem cells (Ly-biased HSCs) subset within the EPCR+CD150 − CD48 − LSK (HSC2) population, phenotypically termed EPCR + MPP6 (CD34 − CD135 − HSC2), that not only displayed comparable multi-lineage potential with HSC in young mice, but also maintained similar lymphoid-biased reconstitution during aging. The lymphoid-biased characteristics of EPCR + MPP6 were also supported by immune associated program at transcriptome and proteomic levels. Notably, EPCR + MPP6 and HSCs rarely generated one another following the first cell division in vitro and under homeostasis in vivo indicating the most likely independent relationship between them and an earlier-than-thought bifurcation of the lymphoid differentiation pathway, which may function as a backup source to support lymphopoiesis. Collectively, this newly defined Ly-biased HSCs represent a promising cellular target for both mechanistic studies and therapeutic strategies concerning age-related immune decline. Highlights: The self-renewable lymphoid-biased hematopoietic stem cells (Ly-biased HSCs) are identified in mice. Unlike HSCs, the Ly-biased HSCs maintain substantial lymphoid potential during ageing. Ly-biased HSCs initiate an alternative lymphoid differentiation pathway which is likely independent from conventional multipotent HSCs.
Open AccessThe self-renewing lymphoid-biased hematopoietic stem cells support long-term lymphopoiesis in mice
Lymphopoiesis is profoundly impaired during ageing largely due to ageing-susceptible changes of hematopoietic stem cells (HSCs). How to maximize the preservation of lymphopoiesis during ageing remains unknown and whether there exists a specific population with life-long lymphoid potential not intensively affected by ageing is of substantial scientific and translational significance. Here, we identified a self-renewable, lymphoid-biased hematopoietic stem cells (Ly-biased HSCs) subset within the EPCR+CD150 − CD48 − LSK (HSC2) population, phenotypically termed EPCR + MPP6 (CD34 − CD135 − HSC2), that not only displayed comparable multi-lineage potential with HSC in young mice, but also maintained similar lymphoid-biased reconstitution during aging. The lymphoid-biased characteristics of EPCR + MPP6 were also supported by immune associated program at transcriptome and proteomic levels. Notably, EPCR + MPP6 and HSCs rarely generated one another following the first cell division in vitro and under homeostasis in vivo indicating the most likely independent relationship between them and an earlier-than-thought bifurcation of the lymphoid differentiation pathway, which may function as a backup source to support lymphopoiesis. Collectively, this newly defined Ly-biased HSCs represent a promising cellular target for both mechanistic studies and therapeutic strategies concerning age-related immune decline. Highlights: The self-renewable lymphoid-biased hematopoietic stem cells (Ly-biased HSCs) are identified in mice. Unlike HSCs, the Ly-biased HSCs maintain substantial lymphoid potential during ageing. Ly-biased HSCs initiate an alternative lymphoid differentiation pathway which is likely independent from conventional multipotent HSCs.
- Open Access
- 26 October 2026
- Published by Springer Nature in Stem Cell Research & Therapy
The bone marrow-gut axis: a bidirectional regulatory network in inflammation, graft-versus-host disease, and aging
- 26 October 2026
- Published by Springer Nature in Stem Cell Research & Therapy
Open AccessThe bone marrow-gut axis: a bidirectional regulatory network in inflammation, graft-versus-host disease, and aging
- 2 September 2026
- Published by Springer Nature in Leukemia
- p. 1-12
KLF4/MLL3 complex axis drives NRBP2 transcription to eliminate acute myeloid leukemia cells
- 2 September 2026
- Published by Springer Nature in Leukemia
- p. 1-12
KLF4/MLL3 complex axis drives NRBP2 transcription to eliminate acute myeloid leukemia cells
- Open Access
- 11 August 2026
- Published by Wolters Kluwer Health in Blood Science
- Vol. 8 (3) , e00307
Tgfbr3 is required for the long-term maintenance of self-renewal potential in murine hematopoietic stem cells
Transforming growth factor-β (TGF-β) signaling plays a crucial role in maintaining the quiescence and self-renewal potential of hematopoietic stem cells (HSCs). Despite decades of research, the underlying mechanisms of TGF-β signaling in HSCs remain elusive due to conflicting phenotypes of various knockout (KO) mouse models. Here, we show that HSCs co-express Tgfbr2 , Tgfbr3 , and Endoglin (Eng ) but rarely express Tgfbr1 , whereas lymphocytes co-express Tgfbr1 and Tgfbr2 but rarely express Tgfbr3 or Eng . We also demonstrate that Tgfbr3 is dispensable for the maintenance of immune homeostasis, in contrast to Tgfbr1 and Tgfbr2 , either of which is essential for lymphocyte homeostasis. Serial transplantation assays revealed that deletion of Tgfbr3 in HSCs had little effect on short-term reconstitution but impaired long-term self-renewal potential, a similar phenotype observed in Eng conditional KO mice. Therefore, we propose that lymphocytes rely on the Tgfbr1/Tgfbr2 complex as suggested by the classical model, whereas HSCs require the unique Tgfbr2/Tgfbr3/Eng complex to orchestrate TGF-β signaling. Collectively, this study reveals Tgfbr3 as a critical regulator in the maintenance of HSC self-renewal potential and suggests a novel TGF-β receptor complex specific to HSCs.
- 11 August 2026
- Published by Wolters Kluwer Health in Blood Science
- Vol. 8 (3) , e00307
Open AccessTgfbr3 is required for the long-term maintenance of self-renewal potential in murine hematopoietic stem cells
Transforming growth factor-β (TGF-β) signaling plays a crucial role in maintaining the quiescence and self-renewal potential of hematopoietic stem cells (HSCs). Despite decades of research, the underlying mechanisms of TGF-β signaling in HSCs remain elusive due to conflicting phenotypes of various knockout (KO) mouse models. Here, we show that HSCs co-express Tgfbr2 , Tgfbr3 , and Endoglin (Eng ) but rarely express Tgfbr1 , whereas lymphocytes co-express Tgfbr1 and Tgfbr2 but rarely express Tgfbr3 or Eng . We also demonstrate that Tgfbr3 is dispensable for the maintenance of immune homeostasis, in contrast to Tgfbr1 and Tgfbr2 , either of which is essential for lymphocyte homeostasis. Serial transplantation assays revealed that deletion of Tgfbr3 in HSCs had little effect on short-term reconstitution but impaired long-term self-renewal potential, a similar phenotype observed in Eng conditional KO mice. Therefore, we propose that lymphocytes rely on the Tgfbr1/Tgfbr2 complex as suggested by the classical model, whereas HSCs require the unique Tgfbr2/Tgfbr3/Eng complex to orchestrate TGF-β signaling. Collectively, this study reveals Tgfbr3 as a critical regulator in the maintenance of HSC self-renewal potential and suggests a novel TGF-β receptor complex specific to HSCs.
- Open Access
- 5 August 2026
- Published by Springer Nature in The EMBO Journal
- Vol. 45 (18) , 6421-6449
P-selectin delineates conserved functional heterogeneity in early hematopoietic stem cell aging in humans and mice
Progressive aging of bone marrow hematopoietic stem cells (HSCs) underlies clonal hematopoiesis and age-associated hematologic disorders. Defining early molecular events driving HSC functional decline is essential for rejuvenation strategies. Here, we identify P-selectin (Selp) as a surface marker that stratifies HSCs into conserved functional and transcriptional states during organismal aging in humans and mice. P-selectin expression increases early during aging and remains elevated in old HSCs. Selp high -HSCs exhibit increased DNA damage and bias towards megakaryocytic/myeloid lineage fate, whereas Selp low -HSCs maintain metabolic integrity, enhanced antioxidant capacity, and reduced myeloid skewing. Transcriptomic analysis revealed that Selp high -HSCs adopt megakaryocytic-primed, pro-inflammatory, and oxidative stress programs, while Selp low -HSCs retain lymphoid-associated and redox-balanced signatures consistent with a more preserved stem-cell state. Further ATAC-seq analysis demonstrates distinct chromatin landscapes with Selp high -HSCs being enriched for inflammatory and platelet-related regulatory elements and CTCF motifs, but Selp low -HSCs displaying accessible ETS-driven networks linked to metabolic fitness and stem cell resilience. Together, these findings uncover conserved heterogeneity during blood stem cell aging and establish P-selectin as an early biomarker and potential therapeutic target to mitigate age-associated hematopoietic decline.
- 5 August 2026
- Published by Springer Nature in The EMBO Journal
- Vol. 45 (18) , 6421-6449
Open AccessP-selectin delineates conserved functional heterogeneity in early hematopoietic stem cell aging in humans and mice
Progressive aging of bone marrow hematopoietic stem cells (HSCs) underlies clonal hematopoiesis and age-associated hematologic disorders. Defining early molecular events driving HSC functional decline is essential for rejuvenation strategies. Here, we identify P-selectin (Selp) as a surface marker that stratifies HSCs into conserved functional and transcriptional states during organismal aging in humans and mice. P-selectin expression increases early during aging and remains elevated in old HSCs. Selp high -HSCs exhibit increased DNA damage and bias towards megakaryocytic/myeloid lineage fate, whereas Selp low -HSCs maintain metabolic integrity, enhanced antioxidant capacity, and reduced myeloid skewing. Transcriptomic analysis revealed that Selp high -HSCs adopt megakaryocytic-primed, pro-inflammatory, and oxidative stress programs, while Selp low -HSCs retain lymphoid-associated and redox-balanced signatures consistent with a more preserved stem-cell state. Further ATAC-seq analysis demonstrates distinct chromatin landscapes with Selp high -HSCs being enriched for inflammatory and platelet-related regulatory elements and CTCF motifs, but Selp low -HSCs displaying accessible ETS-driven networks linked to metabolic fitness and stem cell resilience. Together, these findings uncover conserved heterogeneity during blood stem cell aging and establish P-selectin as an early biomarker and potential therapeutic target to mitigate age-associated hematopoietic decline.
- 1 April 2026
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 22 (4) , 2001-2014
Interleukin-12 Supports Self-renewal Division of Mouse Hematopoietic Stem Cells in Polyvinyl Alcohol-Based Culture
- 1 April 2026
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 22 (4) , 2001-2014
Interleukin-12 Supports Self-renewal Division of Mouse Hematopoietic Stem Cells in Polyvinyl Alcohol-Based Culture
- Open Access
- 26 November 2025
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 10 (4) , 843
Publisher Correction: Large-scale generation of iNK and CAR-iNK cells from CD34+ haematopoietic stem and progenitor cells for adoptive immunotherapy
- 26 November 2025
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 10 (4) , 843
Open AccessPublisher Correction: Large-scale generation of iNK and CAR-iNK cells from CD34+ haematopoietic stem and progenitor cells for adoptive immunotherapy
- Open Access
- 23 October 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (24)
Leukemia-expanded splenic CD81+ erythroblasts potentiate disease progression in mice by reshaping leukemic cell metabolism
During the progression of acute myeloid leukemia (AML), extramedullary hematopoiesis (EMH) compensates for impaired bone marrow hematopoiesis. However, the specific cellular dynamics of EMH and its influence on AML progression remain poorly understood. In this study, we identified a substantial expansion of the CD81 + erythroblast subpopulation (CD81 + Erys) in the spleens of AML mice, which promoted AML cell proliferation and reduced survival. Mechanistically, CD81 + Erys secrete elevated levels of macrophage migration-inhibitory factor (MIF), which interacted with the CD74 receptor on AML cells, activating the mTORC1 signaling pathway and upregulating Egln3 . Consequently, AML cells cocultured with CD81 + Erys exhibited reprogrammed phospholipid metabolism, characterized by an increased phospholipid-to-lysophospholipid ratio. Modulating this metabolic shift, either by supplementing exogenous lysophospholipids or depleting Egln3 in AML cells, restored the phospholipid balance and mitigated the protumorigenic effects induced by CD81 + Erys. Overall, our findings elucidate the molecular crosstalk between erythroblasts and AML cells, extend our insights into the mechanisms driving AML progression, and suggest potential therapeutic strategies.
- 23 October 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (24)
Open AccessLeukemia-expanded splenic CD81+ erythroblasts potentiate disease progression in mice by reshaping leukemic cell metabolism
During the progression of acute myeloid leukemia (AML), extramedullary hematopoiesis (EMH) compensates for impaired bone marrow hematopoiesis. However, the specific cellular dynamics of EMH and its influence on AML progression remain poorly understood. In this study, we identified a substantial expansion of the CD81 + erythroblast subpopulation (CD81 + Erys) in the spleens of AML mice, which promoted AML cell proliferation and reduced survival. Mechanistically, CD81 + Erys secrete elevated levels of macrophage migration-inhibitory factor (MIF), which interacted with the CD74 receptor on AML cells, activating the mTORC1 signaling pathway and upregulating Egln3 . Consequently, AML cells cocultured with CD81 + Erys exhibited reprogrammed phospholipid metabolism, characterized by an increased phospholipid-to-lysophospholipid ratio. Modulating this metabolic shift, either by supplementing exogenous lysophospholipids or depleting Egln3 in AML cells, restored the phospholipid balance and mitigated the protumorigenic effects induced by CD81 + Erys. Overall, our findings elucidate the molecular crosstalk between erythroblasts and AML cells, extend our insights into the mechanisms driving AML progression, and suggest potential therapeutic strategies.